Is Ozempic a peptide?

What the Ozempic label says semaglutide is made of

The Ozempic injection label, revised May 2026, describes the medicine in its Description section. It says Ozempic contains semaglutide. The label calls semaglutide a drug that switches on the cell receptor for the hormone glucagon-like peptide-1, or GLP-1 (a GLP-1 receptor agonist). It also calls it a GLP-1 analog, a changed version of GLP-1.

The label says the peptide backbone is produced by yeast fermentation. A backbone is the main chain of a molecule. Under the IUPAC definition used by chemists, a peptide forms when amino acids link through a bond type called an amide bond. Those links may be called peptide bonds.

IUPAC adds that chains of more than about 50 units are usually called proteins. It also says authors differ on where that line falls. The structure drawing in the Ozempic label numbers the chain from position 7 to position 37. That is 31 amino-acid positions, well under the rough protein line.

The label gives the molecular formula as C187H291N45O59 and the molecular weight as 4113.58 g/mol. Those numbers include the added fatty side chain. A formula on a label describes the molecule in the approved product. It does not test the contents of any other vial, pen or tablet.

How strong is the evidence? For the classification, the record is strong. It comes from the current FDA label for the exact product and the chemists' standard definition.

How semaglutide differs from human GLP-1

The Ozempic label calls GLP-1 a natural hormone with several actions on blood sugar (glucose). It says semaglutide's chain is 94% alike to human GLP-1's chain (94% sequence homology). That figure compares the two amino-acid chains. It does not measure effect or safety.

The label lists three changes to the chain. Position 8 is changed to protect semaglutide from being broken down by an enzyme called DPP-4. The amino acid at position 26 carries a short linker and a fatty part the label calls a C18 fatty di-acid. A small change at position 34 makes sure only one fatty part attaches.

The label says the fatty part lets semaglutide bind to albumin, a protein in the blood. It names that binding as the main reason the medicine lasts so long. The label says blood levels take about 1 week to fall by half (elimination half-life).

A 2015 paper in the Journal of Medicinal Chemistry, by researchers at Novo Nordisk, describes how semaglutide was chosen. It lists two swapped amino acids compared with human GLP-1, at positions 8 and 34. The fatty part is attached at the amino acid lysine at position 26. The team aimed for a once-weekly medicine that resists breakdown.

The labels say the body clears semaglutide mainly by cutting its peptide backbone apart (proteolytic cleavage). The fatty side chain is broken down in steps. About 3% of an injected dose leaves the body in urine as intact semaglutide.

How Ozempic relates to insulin

Some readers ask whether Ozempic is a type of insulin. The Ozempic label says semaglutide lowers blood sugar partly by causing more insulin release when blood sugar is high. It also lowers the release of glucagon, another hormone, at those times. Ozempic acts on the body's own insulin release and does not contain insulin.

Which medicines contain semaglutide

Three brand names cover five semaglutide products in the current labels. Ozempic comes as an injection and as a tablet. Wegovy also comes as an injection and as a tablet. Rybelsus comes as a tablet.

The Ozempic injection label lists three uses in adults with type 2 diabetes. The first is blood sugar control with diet and exercise. The second lowers the risk of major heart events in those with established heart or blood vessel disease. The third lowers the risk of lasting kidney decline, kidney failure and heart-related death in chronic kidney disease.

Major heart events means heart attack, stroke or death from heart or blood vessel disease. Rybelsus and Ozempic tablets share one label, revised January 2026. It lists blood sugar control in adults with type 2 diabetes, with diet and exercise. It also lists lowering the risk of major heart events in adults with type 2 diabetes at high risk.

The Wegovy label, revised June 2026, covers both Wegovy forms, used with a reduced-calorie diet and more physical activity. Both lower the risk of major heart events in adults with established heart or blood vessel disease and obesity or overweight. Both also cover long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition.

The Wegovy injection also covers weight reduction in children 12 and older with obesity. It covers adults with MASH, a liver disease, who have moderate to advanced liver scarring without cirrhosis. FDA gave that use accelerated approval, which may depend on a further trial.

Each use applies to the exact product on its label. A shared active ingredient does not move a use from one label to another. The Wegovy label says using it with other semaglutide products is not recommended.

How the tablets get a peptide into the blood

The tablet label says Rybelsus and Ozempic tablets contain SNAC (salcaprozate sodium), which helps semaglutide get absorbed. Absorption happens mostly in the stomach. For the tablet strengths studied, the label estimates that about 0.4% to 1% of the semaglutide in Rybelsus reaches the blood. For Ozempic tablets, the estimate is about 1% to 2%.

The same label says Rybelsus and Ozempic tablets cannot be swapped for each other milligram for milligram. The Wegovy label also lists SNAC in Wegovy tablets. It reports that blood levels of semaglutide varied more with the tablet than with the injection.

These figures come from each label's pharmacology section. They do not tell a person which form or strength to use. How strong is the evidence? Strong for the named products only, because these are their label statements.

What the peptide answer means for compounded and online semaglutide

FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, covers semaglutide sold outside the approved products. It says compounded drugs are not FDA approved. FDA does not review them for safety, effectiveness or quality before they are marketed.

The same page says some semaglutide products sold by compounders may be salt forms. It names semaglutide sodium and semaglutide acetate. FDA says these are different active ingredients from those used in the approved drugs. FDA says it does not have information on whether they have the same chemical and drug properties.

FDA also reports counterfeit Ozempic in the United States. It has warned companies that sold semaglutide falsely labeled "for research purposes" or "not for human consumption" to consumers. A name on a container does not show what the container holds.

How strong is the evidence? For unapproved products, the record is limited to FDA's warnings. FDA's page gives no test results for any specific product.

Where the classification stops

Calling semaglutide a peptide answers a chemistry question. It does not say who should use it, what dose fits or how a body will respond. Each label lists its own warnings and reasons not to use the medicine (contraindications).

Each semaglutide label carries a boxed warning, FDA's strongest warning, about thyroid C-cell tumors. In mice and rats, semaglutide caused these tumors. The labels say it is unknown whether semaglutide causes them in people. The labels list a personal or family history of medullary thyroid cancer, or of MEN 2, as reasons not to use it.

A licensed clinician can compare a label's reasons not to use a medicine with a person's health history. If a label cited here has changed, report it through the corrections page.